163 related articles for article (PubMed ID: 26312209)
1. Luteolin inhibits progestin-dependent angiogenesis, stem cell-like characteristics, and growth of human breast cancer xenografts.
Cook MT; Liang Y; Besch-Williford C; Goyette S; Mafuvadze B; Hyder SM
Springerplus; 2015; 4():444. PubMed ID: 26312209
[TBL] [Abstract][Full Text] [Related]
2. Natural and synthetic progestins enrich cancer stem cell-like cells in hormone-responsive human breast cancer cell populations in vitro.
Goyette S; Liang Y; Mafuvadze B; Cook MT; Munir M; Hyder SM
Breast Cancer (Dove Med Press); 2017; 9():347-357. PubMed ID: 28579829
[TBL] [Abstract][Full Text] [Related]
3. Progestin-dependent progression of human breast tumor xenografts: a novel model for evaluating antitumor therapeutics.
Liang Y; Besch-Williford C; Brekken RA; Hyder SM
Cancer Res; 2007 Oct; 67(20):9929-36. PubMed ID: 17942925
[TBL] [Abstract][Full Text] [Related]
4. Apigenin induces apoptosis and blocks growth of medroxyprogesterone acetate-dependent BT-474 xenograft tumors.
Mafuvadze B; Liang Y; Besch-Williford C; Zhang X; Hyder SM
Horm Cancer; 2012 Aug; 3(4):160-71. PubMed ID: 22569706
[TBL] [Abstract][Full Text] [Related]
5. Cholesterol biosynthesis inhibitor RO 48-8071 reduces progesterone receptor expression and inhibits progestin-dependent stem cell-like cell growth in hormone-dependent human breast cancer cells.
Liang Y; Goyette S; Hyder SM
Breast Cancer (Dove Med Press); 2017; 9():487-494. PubMed ID: 28744156
[TBL] [Abstract][Full Text] [Related]
6. Curcumin inhibits MPA-induced secretion of VEGF from T47-D human breast cancer cells.
Carroll CE; Ellersieck MR; Hyder SM
Menopause; 2008; 15(3):570-4. PubMed ID: 18467956
[TBL] [Abstract][Full Text] [Related]
7. p53-dependent inhibition of progestin-induced VEGF expression in human breast cancer cells.
Liang Y; Wu J; Stancel GM; Hyder SM
J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):173-82. PubMed ID: 15860260
[TBL] [Abstract][Full Text] [Related]
8. Ligand- and cell-specific effects of signal transduction pathway inhibitors on progestin-induced vascular endothelial growth factor levels in human breast cancer cells.
Wu J; Brandt S; Hyder SM
Mol Endocrinol; 2005 Feb; 19(2):312-26. PubMed ID: 15528272
[TBL] [Abstract][Full Text] [Related]
9. Proliferation of endothelial and tumor epithelial cells by progestin-induced vascular endothelial growth factor from human breast cancer cells: paracrine and autocrine effects.
Liang Y; Hyder SM
Endocrinology; 2005 Aug; 146(8):3632-41. PubMed ID: 15845615
[TBL] [Abstract][Full Text] [Related]
10. Luteolin suppresses development of medroxyprogesterone acetate-accelerated 7,12-dimethylbenz(a)anthracene-induced mammary tumors in Sprague-Dawley rats.
Cook MT; Mafuvadze B; Besch-Williford C; Ellersieck MR; Goyette S; Hyder SM
Oncol Rep; 2016 Feb; 35(2):825-32. PubMed ID: 26719029
[TBL] [Abstract][Full Text] [Related]
11. The anticancer agent YC-1 suppresses progestin-stimulated VEGF in breast cancer cells and arrests breast tumor development.
Carroll CE; Liang Y; Benakanakere I; Besch-Williford C; Hyder SM
Int J Oncol; 2013 Jan; 42(1):179-87. PubMed ID: 23123638
[TBL] [Abstract][Full Text] [Related]
12. Progestin regulation of vascular endothelial growth factor in human breast cancer cells.
Hyder SM; Murthy L; Stancel GM
Cancer Res; 1998 Feb; 58(3):392-5. PubMed ID: 9458078
[TBL] [Abstract][Full Text] [Related]
13. Apigenin prevents development of medroxyprogesterone acetate-accelerated 7,12-dimethylbenz(a)anthracene-induced mammary tumors in Sprague-Dawley rats.
Mafuvadze B; Benakanakere I; López Pérez FR; Besch-Williford C; Ellersieck MR; Hyder SM
Cancer Prev Res (Phila); 2011 Aug; 4(8):1316-24. PubMed ID: 21505181
[TBL] [Abstract][Full Text] [Related]
14. Synthetic progestins induce growth and metastasis of BT-474 human breast cancer xenografts in nude mice.
Liang Y; Benakanakere I; Besch-Williford C; Hyder RS; Ellersieck MR; Hyder SM
Menopause; 2010; 17(5):1040-7. PubMed ID: 20461021
[TBL] [Abstract][Full Text] [Related]
15. Progestin-dependent induction of vascular endothelial growth factor in human breast cancer cells: preferential regulation by progesterone receptor B.
Wu J; Richer J; Horwitz KB; Hyder SM
Cancer Res; 2004 Mar; 64(6):2238-44. PubMed ID: 15026368
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological and endogenous progestins induce vascular endothelial growth factor expression in human breast cancer cells.
Hyder SM; Chiappetta C; Stancel GM
Int J Cancer; 2001 May; 92(4):469-73. PubMed ID: 11304678
[TBL] [Abstract][Full Text] [Related]
17. The estrogenic activity of synthetic progestins used in oral contraceptives enhances fatty acid synthase-dependent breast cancer cell proliferation and survival.
Menendez JA; Oza BP; Colomer R; Lupu R
Int J Oncol; 2005 Jun; 26(6):1507-15. PubMed ID: 15870863
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms involved in the evolution of progestin resistance in human breast cancer cells.
Murphy LC; Dotzlaw H; Wong MS; Miller T; Murphy LJ
Cancer Res; 1991 Apr; 51(8):2051-7. PubMed ID: 1849041
[TBL] [Abstract][Full Text] [Related]
19. Cyproterone, norethindrone, medroxyprogesterone and levonorgestrel are less potent local human growth hormone and insulin-like growth factor I secretion stimulators than progesterone in human breast cancer explants expressing the estrogen receptor.
Milewicz T; Kolodziejczyk J; Krzysiek J; Basta A; Sztefko K; Kurek S; Stachura J; Gregoraszczuk EL
Gynecol Endocrinol; 2002 Aug; 16(4):319-29. PubMed ID: 12396561
[TBL] [Abstract][Full Text] [Related]
20. Effects of MDM2 inhibitors on vascular endothelial growth factor-mediated tumor angiogenesis in human breast cancer.
Xiong J; Yang Q; Li J; Zhou S
Angiogenesis; 2014 Jan; 17(1):37-50. PubMed ID: 23907365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
